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The treatment of breast cancer has progressed amazingly 
during the past three decades but a relatively high 
proportion of patients still experience resistance to 
pharmacotherapy (i.e., endocrine therapy, chemotherapy, 
and HER2-directed antibody-drugs) (1,2). Lately, two 
immune checkpoint inhibitors have been approved in several 
countries for the treatment of breast cancer. Specifically, 
atezolizumab (Tecentriq®, Genentech Inc, South San 
Francisco, CA, USA), an anti-programmed death-ligand 
1 (PD-L1) drug, and pembrolizumab (Keytruda®, Merck 
& Co. Inc., Kenilworth, NJ, USA), that blocks PD-L1 
receptor programmed cell death protein 1 (PD-1). Ongoing 
phase II and III trials are expected to lead to more approvals 
in different clinical settings. 
At present, breast cancer immunotherapy is biomarker-
based (3). In unresectable locally advanced or metastatic 
triple-negative breast cancers (TNBC), only cases in which 
the tumor-infiltrating immune cells express PD-L1 in ≥1% 
of the tumor area can be treated with atezolizumab (4). The 
VENTANA PD-L1 (SP142) Assay (Roche Tissue Diagnostics, 
Tucson, AZ, USA) comes as a companion diagnostic (CDx) 
test for this analysis. Results of KEYNOTE-355 recently 
presented at ASCO 2020 revealed progression-free survival 
benefits of pembrolizumab plus chemotherapy in high PD-L1 
expression TNBC. However, this analysis is not yet part of the 
everyday in clinical practice. On the other hand, the Food and 
Drug Administration (FDA) approved pembrolizumab in all 
refractory advanced solid tumors with mismatch repair (MMR) 
deficiency and/or high levels of microsatellite instability 
(MSI) (5). Regrettably, our knowledge on the specific biology 
of MMR deficiency in breast cancer is limited, both in terms 
of identifying relative contributions of this system to patient 
outcomes and in understanding the role of cellular localization 
of MMR proteins to cancer phenotypes. 
Genomic scars in the MMR system occur at relatively low 
frequency in breast cancer and are reported in approximately 
2% of cases. However, this subject is controversial in literature 
given the lack of CDx and/or tumor-specific guidelines for 
MMR analysis (6-11). Hence, MMR data in breast cancer 
may vary according to the testing method employed, such as 
direct sequencing of microsatellite markers, next-generation 
sequencing (NGS), and immunohistochemistry (IHC) for the 
four MMR proteins (Table 1). To date, a constellation of locally 
developed tests can be found (12). These are generally modeled 
on those approved for colorectal and endometrial carcinomas, 
where MSI is more frequent (15% and 20–30%, respectively) 
than in breast cancer (13,14). It needs to be highlighted that 
in these types of cancer, MMR and MSI testings were not 
standardized to inform immunotherapy decisions but for the 
screening of Lynch syndrome, an inherited disorder caused by 
germline defects in the MMR systems (15). 
The mechanisms underpinning the possible susceptibility 
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of MMR-deficient breast cancers to immune-checkpoint 
blockade is not trivial. Dysfunction in the MMR system 
may result in a hypermutator state, with subsequent neo-
antigen generation by the neoplastic cells and activation of 
the adaptative immune response (16). On the other hand, 
MMR defects in breast cancer induce an increase in tumor 
mutation burden (TMB) that is many orders of magnitude 
lower than that seen in archetypal Lynch syndrome 
spectrum cancers (17,18). Hence, there may be essential 
differences in how MMR functions in breast compared to 
other cancer sites. 
Clinicopathologic features of MMR-deficient 
breast cancers
In this scenario, a recently published study of Cheng et al. (6) 
has provided important insights. The Authors profiled 
the expression of the four key MMR proteins [i.e., mutL 
homolog 1 (MLH1), PMS1 Homolog 2 (PMS2), mutS 
homolog 2 (MSH2), and mutS homolog 6 (MSH6)] by 
IHC on a large series of breast cancer patients. Their main 
objective was to better understand the clinical meaning of 
MMR deficiency in breast cancer, particularly in terms of 
long-term outcomes. Out of 3,992 tumors embedded in 
tissue microarrays, 1,635 (41%) cases were interpretable. 
Among them, 31 (2%) breast cancers showed the loss of 
nuclear staining for at least one of the MMR proteins, 
being identified as MMR deficient. Unlike endometrial and 
colorectal cancers, the majority of patients from the study 
of Cheng et al. presented with a single protein loss (n=25, 
81%) while the remaining 6 (19%) cases had pair loss (Figure 
1). Interestingly, the MutLα complex, which is composed 
of MLH1 and PMS2, was more targeted by alterations 
than MutSα  (i.e., MSH2 and MSH6). The highest 
frequency of MMR deficiency was observed in Luminal 
breast cancers (n=22, 71%), as previously observed (8). 
The authors reported a specific correlation with high 
grade, low progesterone receptor (PR) expression, and 
high tumor-infiltrating lymphocytes (TILs) counts. 
However, the low proportion of MMR deficient samples 
precludes a conclusive understanding of the incidence rate 
variance between specific subclasses of patients. It could be 
argued that the connection between MMR deficiency and 
high histologic grade may be due to a higher TMB (19). 
However, mutations in known oncogenic drivers are not 
statistically enriched in MMR-defective relative to MMR-
proficient breast cancers (11). 
The overall chemical integrity of the MMR system has 
been related to patients’ prognosis in several cancer types (20). 
Cheng et al. showed a non-significant decrease in the 
Table 1 Studies on mismatch repair (MMR) status and breast cancer
Authors Ref. Year Testing method Nr. of patients dMMR (%)
Cheng et al. (6) 2020 IHC 1,635 1.9
Lopez et al. (7) 2020 IHC 608 13.3
Fusco et al. (8) 2018 IHC & MSI 444 17
Lee et al. (9) 2019 Sanger Sequencing, IHC, MSI 94 3.2
Le et al. (10) 2017 NGS N/A <2
Davies et al. (11) 2017 WGS 640 1.7
dMMR, MMR deficiency; IHC, immunohistochemistry; MSI, microsatellite instability; NGS, next-generation sequencing; WGS,  
whole-genome sequencing.
Figure 1 Frequency and patterns of mismatch repair protein loss 
across 31 mismatch repair deficient breast cancers from the British 
Columbia cohort.
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overall survival and breast cancer disease-specific survival 
across all breast cancer types. However, the analyses based 
on treatment showed that estrogen receptor (ER)-positive 
patients with MMR deficiency who received tamoxifen 
as adjuvant systemic therapy had worse survival. Of note, 
dysfunctions of the MutLα complex are related to resistance 
phenomena to all classes of endocrine therapy in breast 
cancer (21-23). This observation also argues against high 
TMB caused by MMR deficiency as the driver of poor 
outcomes, since MMR deficiency increases mutational 
load across breast cancer subtypes, and yet associates with 
poor outcomes only in ER+ patients (24). All these diverse 
observations highlight the importance of MMR testing/
screening in breast cancer patients.
Real-life challenges in MMR clinical testing
Investigating MMR-deficiencies in breast cancer is not 
an easy task. Several issues in MMR clinical testing are 
related to the limitations of the existing methods and the 
absence of CDx and/or tumor-specific guidelines. Despite 
immunohistochemistry of the four MMR proteins and 
MSI testing being widely applied, these tests are not 
interchangeable in breast cancer since MMR protein loss 
is more commonly detected than MSI (8). Of note, not 
all MMR proteins equally impact either mutation load 
or MSI when defective. It remains to be determined how 
much the MMR status assessment is troubled by technical 
artifacts and/or intra-tumor heterogeneity phenomena. On 
the other hand, accumulating evidence on the significant 
prognostic value of MMR IHC in breast cancer seems 
to suggest the clinical validity of this test (6-8). To this 
end, specific antibody clones, CDx, and/or interpretation 
guidelines are warranted. Methylation-specific PCR for 
testing hypermethylation of MLH1 promoter akin somatic 
variant screening through NGS is usually performed as 
verification methods (12). However, in breast cancer, a 
tumor-specific panel of genes would be required to test 
any possible association of MMR deficiency with other 
clinically actionable genes. Finally, TMB is another 
emerging biomarker (25). Increased TMB was found in 
tumors with defects in the MMR system, thus, it could 
be used as a surrogate diagnostic assay. Unfortunately, 
TMB analysis is neither time nor cost-effective while it 
may prove misleading in cases of unsuitable NGS panels. 
Also, as in the case of MSI, TMB does not provide insight 
into which individual MMR protein is defective in a given 
patient tumor. Finally, there are no guidelines on the genes 
to include in the TMB count. Hence, whole-exome TMB-
high tumors may not be related to MMR deficiency and/or 
worse prognosis (18). All these methods represent candidate 
tools for MMR testing in breast cancer, but they need to be 
profoundly tested in order to overcome existing limitations 
and make routine testing feasible. 
The study of Cheng et al. has added great value to this 
topic, mostly by assessing the clinical meaning of MMR 
deficiency in the largest cohort of breast cancer patients 
thus far, while it brought to light several disadvantages of 
existing techniques. Due to the high degree of intratumor 
heterogeneity that characterizes breast cancer, sampling and 
analyzing different topographic areas of the same tumor 
could be more reliable. This intratumor heterogeneity 
is also specifically true for MLH1 expression, where 
mutational analyses demonstrate that MLH1 mutations 
are not founders but only occur in specific subclonal 
populations. It would be helpful for IHC analysis to be 
combined with genomic analysis in order to increase the 
sensitivity and specificity. 
At the moment, only a few studies have tried to 
investigate MMR-deficiency in breast cancer, but their 
results are not in consensus. Considering the limitations of 
these studies, it is evident that locally developed methods 
present disadvantages and inadequate reproducibility. 
Therefore, tumor-specific guidelines, companion and 
complementary diagnostics, as well as surrogate biomarkers, 
are necessary for a targeted MMR status assessment in 
breast cancer. It is fair to conclude that improvements in 
MMR testing are necessary in order to enable its application 
in clinical practice.
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